Baseline and the changes of neutrophil-to-lymphocyte ratio throughout chemoradiotherapy in nasopharyngeal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20220810006

Enrollment

Registered

2022-08-10

Start date

2022-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal cancer nasopharyngeal cancer NPC chemoradiotherapy neutrophil to lymphocyte ratio NLR inflammatory survival

Interventions

Patients underwent radiotherapy with concurrent weekly carboplatin then three cycles of adjuvant carboplatin and 5-FU

Diagnostic

CCRT followed by adjuvant chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. age 18-70 years old 2. histology-proven WHO type 2 NPC, stage T2N0M0-T4N2M0 (AJCC 7th edition) 3. Eastern Cooperative Oncology Group performance status 0-1 4. adequate bone marrow function, and serum creatinine clearance not less than 30 mL per min

Exclusion criteria

Exclusion criteria: N3 or metastatic disease

Design outcomes

Primary

Measure	Time frame
Neutrophil-to-lymphocyte ratio Start concurrent chemoradiotherapy Blood test,Neutrophil-to-lymphocyte ratio End of concurrent chemoradiotherapy Blood test,Neutrophil-to-lymphocyte ratio End of adjuvant chemotherapy Blood test	—

Secondary

Measure	Time frame
Overall survival Last visit Patient status from medical records	—

Countries

Thailand

Contacts

Public ContactPooriwat Muangwong

Faculty of Medicine, Chiang Mai University

pooriwat.m@cmu.ac.th6653935450

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026